Sign In
to Vote &
Create Storyboards.
 
In two early stage studies, Bristol-Myers Squibb's nivolumab and Merck's pembrolizumab shrank tumors in patients with Hodgkin's lymphoma.
6
0
0


Storyboard
Print
Share this Article



Comment on this Article

Please Sign In to comment

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard